Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Not Yet Opened 03-11 16:00:00 EDT

73.61

-0.40

-0.53%

High74.29	Low73.34	Vol1.04B
Open74.00	D1 Closing74.00	Amplitude1.29%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O15.84B	T/O Rate--	Tradable Shares0.00
P/B7.181659	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":73.60753,"timestamp":1773259199999,"preClose":74.00321,"halted":0,"volume":1044763872,"delay":0,"changeRate":-0.005347,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-0.395683,"latestTime":"03-11 16:00:00 EDT","open":74.00335,"high":74.29178,"low":73.3364,"amount":15836480375.07429,"amplitude":0.01291,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773302400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.181659,"peRate":-188.024099,"turnoverRate":0.031032,"increases":180,"decrements":313,"flats":20,"marketCap":1898500718739.9375,"floatMarketCap":1714025885441.5},"requestUrl":"/m/hq/s/BK4139/wiki","defaultTab":"wiki","newsList":[{"id":"2618906033","title":"Alterity Therapeutics Launches Facility to Sell Small Share Parcels","url":"https://stock-news.laohu8.com/highlight/detail?id=2618906033","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618906033?lang=en_us&edition=fundamental","pubTime":"2026-03-12 10:43","pubTimestamp":1773283404,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alterity Therapeutics has introduced an opt-out unmarketable parcel sale f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-launches-facility-to-sell-small-share-parcels?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-launches-facility-to-sell-small-share-parcels?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2618903055","title":"Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2618903055","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618903055?lang=en_us&edition=fundamental","pubTime":"2026-03-12 09:49","pubTimestamp":1773280183,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Oragenics ( ($OGEN) ). Oragenics has secured final ethics approval in Australia to begin a Phase IIa clinical t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oragenics-advances-concussion-drug-trial-and-explores-cns-asset-acquisitions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oragenics-advances-concussion-drug-trial-and-explores-cns-asset-acquisitions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","OGEN","CNS","BK4139"],"gpt_icon":0},{"id":"2618905241","title":"UniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh","url":"https://stock-news.laohu8.com/highlight/detail?id=2618905241","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618905241?lang=en_us&edition=fundamental","pubTime":"2026-03-12 09:36","pubTimestamp":1773279364,"startTime":"0","endTime":"0","summary":"uniQure (NasdaqGS:QURE) faces multiple securities class action lawsuits focused on disclosures around its AMT-130 gene therapy program.\nFederal health officials have criticized the company for alleged data manipulation tied to AMT-130.\nThe FDA has withdrawn support for a Biologics License Application for AMT-130, complicating the program's regulatory path.\nUpcoming changes in FDA leadership are expected to affect how AMT-130 and related filings are reviewed.\n\nThese developments arrive at a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-faces-amt-130-scrutiny-as-fda-shifts-and-lawsuits-we","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-faces-amt-130-scrutiny-as-fda-shifts-and-lawsuits-we","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4581","BK4585","BK4534","BK4588","LU0109394709.USD","BK4084","QURE","LABU","LU0320765992.SGD","BK4139","BK4554","LU0889565916.HKD","AMT","BK4219"],"gpt_icon":0},{"id":"2618903578","title":"Foghorn Advances FHD-909 Trial and Strengthens Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2618903578","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618903578?lang=en_us&edition=fundamental","pubTime":"2026-03-12 09:29","pubTimestamp":1773278945,"startTime":"0","endTime":"0","summary":"Foghorn Therapeutics ( ($FHTX) ) has provided an update. Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/foghorn-advances-fhd-909-trial-and-strengthens-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/foghorn-advances-fhd-909-trial-and-strengthens-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FHTX","BK4139"],"gpt_icon":0},{"id":"2618490843","title":"Relay Therapeutics Updates Bylaws on Federal Securities Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2618490843","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618490843?lang=en_us&edition=fundamental","pubTime":"2026-03-12 09:21","pubTimestamp":1773278462,"startTime":"0","endTime":"0","summary":"Relay Therapeutics ( ($RLAY) ) just unveiled an update. On March 6, 2026, Relay Therapeutics, Inc. amended and restated its bylaws to specify that ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/relay-therapeutics-updates-bylaws-on-federal-securities-litigation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/relay-therapeutics-updates-bylaws-on-federal-securities-litigation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLTW","BK4563","US12M.BOND","US5Y.BOND","RLAY","US10Y.BOND","US30Y.BOND","TMF","US7Y.BOND","US3Y.BOND","BK4139","US6M.BOND","US2Y.BOND"],"gpt_icon":0},{"id":"2618084559","title":"BioXcel Therapeutics Announces Registered Direct Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618084559","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618084559?lang=en_us&edition=fundamental","pubTime":"2026-03-12 09:09","pubTimestamp":1773277785,"startTime":"0","endTime":"0","summary":"Bioxcel Therapeutics ( ($BTAI) ) just unveiled an update. On March 10, 2026, BioXcel Therapeutics, Inc. entered into a securities purchase agreemen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioxcel-therapeutics-announces-registered-direct-equity-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioxcel-therapeutics-announces-registered-direct-equity-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","EQR","BK4215","BK4007","BK4585","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2618970218","title":"Anixa Biosciences Shareholders Back Board and Compensation","url":"https://stock-news.laohu8.com/highlight/detail?id=2618970218","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618970218?lang=en_us&edition=fundamental","pubTime":"2026-03-12 09:00","pubTimestamp":1773277225,"startTime":"0","endTime":"0","summary":"An update from Anixa Biosciences ( ($ANIX) ) is now available. On March 10, 2026, Anixa Biosciences, Inc. held its 2026 annual meeting of stockhold...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/anixa-biosciences-shareholders-back-board-and-compensation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/anixa-biosciences-shareholders-back-board-and-compensation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2618970241","title":"Outlook Therapeutics Announces Board Resignation and Size Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2618970241","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618970241?lang=en_us&edition=fundamental","pubTime":"2026-03-12 08:51","pubTimestamp":1773276682,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics ( ($OTLK) ) has issued an update. On March 6, 2026, Outlook Therapeutics’ board accepted the resignation of director Dr. Julia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-announces-board-resignation-and-size-reduction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-announces-board-resignation-and-size-reduction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2618977732","title":"ContextLogic Director and 10% Owner Bobbili Raja Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618977732","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618977732?lang=en_us&edition=fundamental","pubTime":"2026-03-12 08:35","pubTimestamp":1773275712,"startTime":"0","endTime":"0","summary":"Bobbili Raja, a director and 10% owner of ContextLogic Holdings Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ContextLogic Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL5kY5Kz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ContextLogic Director and 10% Owner Bobbili Raja Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4220","LOGC"],"gpt_icon":0},{"id":"2618972290","title":"Equillium COO Christine Zedelmayer Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618972290","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618972290?lang=en_us&edition=fundamental","pubTime":"2026-03-12 08:12","pubTimestamp":1773274321,"startTime":"0","endTime":"0","summary":"Christine Zedelmayer, Sr. Vice President and COO of Equillium, Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL20cpv7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Equillium COO Christine Zedelmayer Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EQ","BK4568"],"gpt_icon":0},{"id":"2618997754","title":"Caris Life Sciences Signals Strong Growth and Ambition","url":"https://stock-news.laohu8.com/highlight/detail?id=2618997754","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618997754?lang=en_us&edition=fundamental","pubTime":"2026-03-12 08:11","pubTimestamp":1773274294,"startTime":"0","endTime":"0","summary":"Caris Life Sciences, Inc. (($CAI)) has held its Q4 earnings call. Read on for the main highlights of the call. Caris Life Sciences’ latest earnings...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/caris-life-sciences-signals-strong-growth-and-ambition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/caris-life-sciences-signals-strong-growth-and-ambition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAI","BK4104","BK4139"],"gpt_icon":0},{"id":"2618502972","title":"Soleno Therapeutics faces class action over DCCR trial disclosures after 27% stock drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2618502972","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618502972?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:54","pubTimestamp":1773273266,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit was filed on behalf of investors who bought Soleno common stock between March 26, 2025 and November 4, 2025. The complaint alleges Soleno misled investors about safety risks and commercial viability tied to its Phase 3 program for diazoxide choline extended-release tablets , including concerns about fluid retention. It also cites a Scorpion Capital report published on August 15, 2025, after which Soleno shares fell about 12% over two trading days. The filing says Soleno disclosed on September 10, 2025 that a patient died after taking DCCR, and the stock fell about 19% over two trading days. The complaint further states that after Soleno discussed launch disruption and higher discontinuations on November 4, 2025, the shares dropped about 27% in one day.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL1Zlbdy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4112","IE00B64PRP62.GBP","BK4588","LU2095319765.USD","SG9999014013.SGD","SLNO","LU2210149790.SGD","SG9999014005.SGD","SG9999014021.USD","NDAQ","BK4585","LU2210150020.SGD","LU0314104364.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4139"],"gpt_icon":0},{"id":"2618117972","title":"EQ Resources Updates Market on Lapse of Listed Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2618117972","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618117972?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:48","pubTimestamp":1773272903,"startTime":"0","endTime":"0","summary":"EQ Resources Limited ( ($AU:EQR) ) has issued an announcement. EQ Resources Limited has notified the market of a change to its capital structure vi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-updates-market-on-lapse-of-listed-options?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-updates-market-on-lapse-of-listed-options?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQ","BK4568","BK4139"],"gpt_icon":0},{"id":"1149692976","title":"BEIGENE Allots 741,300 Shares Under Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1149692976","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149692976?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:48","pubTimestamp":1773272890,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced the issuance of 741,300 shares on March 11, 2026, in accordance with its equity incentive plan.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK4588","BK4139","BK1588","LU1303224171.USD","LU1719994722.HKD","BK4585","BK1500","BK0239","BK4526","LU2328871848.SGD","06160","BK1583","ONC","BK1161","LU0307460666.USD","LU1969619763.USD","LU0588546209.SGD","LU1770034418.SGD","LU1251922891.USD"],"gpt_icon":0},{"id":"2618972579","title":"Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2618972579","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618972579?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:46","pubTimestamp":1773272760,"startTime":"0","endTime":"0","summary":"SINGAPORE, March 12, 2026 /PRNewswire/ -- Locus Cell Co., Ltd. , a Taiwan-based cell and gene therapy  Contract Development and Manufacturing Organization , and Charles River Laboratories , a global contract research organization  providing drug development support and biologics testing solutions, have signed a Memorandum of Understanding  during the APAC Biomanufacturing Leadership Summit 2026 in Singapore.Sean Chang , CEO of Locus Cell, and Nadiya Kravchuk , Senior Director of APAC Biologics Manufacturing at Charles River Laboratories, at the Memorandum of Understanding  signing during the APAC Biomanufacturing Leadership Summit 2026 in Singapore. Photo courtesy of Charles River Laboratories.The Summit, positioned as the flagship APAC biomanufacturing forum, convened regional executives, investors, regulatory experts, and scientists under the theme \"Shaping the Region's Bioproduction Landscape – From Scale-Up Innovation to Quality Compliance.\" Discussions centered on strengthening re","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2932147/image.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2932147/image.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/locus-cell-taiwan-based-cell-and-gene-therapy-cdmo-signs-mou-with-charles-river-at-apac-biomanufacturing-leadership-summit-302711618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CDMO","BK7500","SMMF","BK4211","CRO.AU","APAC"],"gpt_icon":0},{"id":"2618972839","title":"EQ Resources Seeks ASX Quotation for 13.7 Million New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618972839","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618972839?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:38","pubTimestamp":1773272326,"startTime":"0","endTime":"0","summary":"The latest update is out from EQ Resources Limited ( ($AU:EQR) ). EQ Resources Limited has applied to the ASX for quotation of 13,742,830 new ordin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-seeks-asx-quotation-for-13-7-million-new-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-seeks-asx-quotation-for-13-7-million-new-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQ","BK4568","BK4139"],"gpt_icon":0},{"id":"2618974247","title":"United Therapeutics Chairperson and CEO Martine A Rothblatt Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618974247","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618974247?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:32","pubTimestamp":1773271951,"startTime":"0","endTime":"0","summary":"Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corporation, reported a disposal of common shares of United Therapeutics Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL6MGL8N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"United Therapeutics Chairperson and CEO Martine A Rothblatt Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1699723380.USD","LU1571399168.USD","BK4139","UTHR"],"gpt_icon":0},{"id":"1173054555","title":"Rise of Heavy Assets: Power Sector Gains Over 13% Year-to-Date, How to Position in A-Shares Under HALO Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1173054555","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173054555?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:32","pubTimestamp":1773271948,"startTime":"0","endTime":"0","summary":"In recent months, the HALO trading strategy—centered on \"Heavy Assets and Low Obsolescence\"—has gained popularity on Wall Street.  Concerns over \"rapid AI innovation disrupting asset-light business...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159982","HALO","399300","LU0053671581.USD","159146","BK4139"],"gpt_icon":0},{"id":"2618797413","title":"Mesoblast appoints Teresa Montagut as Head of Clinical Development and Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2618797413","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618797413?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271313,"startTime":"0","endTime":"0","summary":"Mesoblast appointed Teresa Montagut as Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Eric Rose. Montagut will lead the medical affairs organization and support investigator-initiated trials and clinical collaborations. She joined Mesoblast from Regeneron, where she was Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs for Investigator Sponsored Studies in gastrointestinal and genitourinary areas. Mesoblast said Montagut will support efforts to expand indications for its cell therapy programs in pediatric and adult inflammatory conditions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbkSytc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","IE00BGHQF748.EUR","LU2362541513.USD","IE00BKPKM429.USD","LU2362541273.HKD","LU2237438978.USD","IE00B64PRP62.GBP","REGN","SG9999014013.SGD","SG9999014039.USD","BK4585","LU0314104364.USD","LU0889565916.HKD","NDAQ","LU0823434583.USD","MSB.AU","LU1974910355.USD","LU0823416689.USD","LU0058720904.USD","LU0882574055.USD","BK4588","SG9999014005.SGD","LU0823434740.USD","BK4139","LU2023250504.SGD","LU2210149790.SGD","LU0114720955.EUR","BK7067","IE00B3QW5Z07.USD","LU0289739699.SGD","LU0320765992.SGD","BK7501","LU0109394709.USD","SG9999014021.USD","LU2106854487.HKD","LU2362540622.SGD","LU2095319765.USD","BK7508","LU2089984988.USD","LU0053666078.USD","LU2210150020.SGD","BK4112","LU1917777945.USD"],"gpt_icon":0},{"id":"2618597413","title":"Xenon Pharmaceuticals President and CEO Ian Mortimer Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618597413","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618597413?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271263,"startTime":"0","endTime":"0","summary":"Ian Mortimer, President and CEO and a director of Xenon Pharmaceuticals Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL6W8hRy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon Pharmaceuticals President and CEO Ian Mortimer Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0254},{"period":"3month","weight":-0.0186},{"period":"6month","weight":0.0288},{"period":"1year","weight":0.2166},{"period":"ytd","weight":-0.0082}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}